Aprea Therapeutics, Inc. — Director's Dealing 2021

Sep 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aprea Therapeutics, Inc. (APRE)
CIK: 0001781983
Period of Report: 2021-09-10

Reporting Person: Korbel Gregory Alan (Chief Business Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-10	Common Stock	F	1724	$4.59	Disposed	22627	Direct

Footnotes

F1: Represents shares withheld to satisfy tax withholding obligations in connection with the vesting of 5,000 restricted stock units.